Drugmakers Assail FDA For Nixing Generic Laxative Approval

Law360 (April 10, 2018, 9:01 PM EDT) -- Two drugmakers are attacking the U.S. Food and Drug Administration for rescinding approvals of generic versions of a Bayer AG laxative, warning of higher costs and "serious medical ramifications" for patients.

Breckenridge Pharmaceutical Inc. and Nexgen Pharma Inc. voiced the criticism in a citizen petition released Monday. The petition, which threatened a legal challenge, urged the FDA to delay its scheduled withdrawal of approvals for their generic versions of Bayer's MiraLAX, or polyethylene glycol 3350.

MiraLAX won approval in 1999 as a prescription drug, with generic versions entering the market later. It eventually converted to an over-the-counter drug. The FDA generally...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!